<DOC>
	<DOC>NCT01051024</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of Diamel administration in the treatment of Polycystic Ovary Syndrome. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks.</brief_summary>
	<brief_title>Diamel in the Treatment of Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<criteria>Two of the following criteria: Oligo or Anovulation Polycystic Ovary diagnosed by ultrasound technique Clinical signs of Hyperandrogenism Signed informed consent Personal history of other causes of hyperandrogenism: Hyperprolactinemia, suprarenal tumors, ovary tumors, suprarenal hyperplasia, hypercortisolism. Patients under other experimental treatment Treatment with ovulation inducers and/or insulin sensitizers within 60 days before treatment Treatment with vitamins within 7 days before treatment Treatment with dietary supplements within 60 days before treatment Noncompensated intercurrent diseases: diabetes mellitus, thyroid disease, hypertension</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Dietary supplement</keyword>
	<keyword>Diamel</keyword>
	<keyword>Polycystic Ovary Syndrome</keyword>
	<keyword>Female Infertility</keyword>
</DOC>